Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Down 13.6% in December

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the recipient of a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 117,900 shares, a drop of 13.6% from the November 30th total of 136,400 shares. Approximately 6.6% of the shares of the company are sold short. Based on an average daily trading volume, of 562,900 shares, the short-interest ratio is currently 0.2 days.

Lixte Biotechnology Trading Up 1.5 %

Shares of NASDAQ:LIXT traded up $0.03 during midday trading on Tuesday, hitting $2.03. The stock had a trading volume of 37,325 shares, compared to its average volume of 309,402. Lixte Biotechnology has a 1 year low of $1.31 and a 1 year high of $4.40. The stock has a 50 day moving average price of $1.89 and a two-hundred day moving average price of $2.03. The company has a market capitalization of $4.57 million, a PE ratio of -1.17 and a beta of -0.11.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.